Canopy Growth Corporation
NASDAQ:CGCDrug Manufacturers - Specialty & Generic
+$0.01 today
- Market cap
- $212.31M
- Beta
- 0.78
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.76
Volume 3.44M
Average 9.97M
CGC Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Canopy Growth CorporationNASDAQ: CGC
Research & Development · Q4 FY2025 · quarter ended Mar 2026
Research & development remains negative
Q4 FY2025 research & development was CA$0, compared with CA$2.74M a year earlier. Trailing-twelve-month research & development was CA$0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, down 0.7 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near CA$0 or moves back toward the trailing-twelve-month quarterly average of CA$0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
CAD · from the income statement
- Latest · FY2025
- 0 CAD
- Year-over-year change
- -100.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2026-03-31 | 0 | -100.0% |
| FY2024 | 2025-03-31 | 1.91M | -58.7% |
| FY2023 | 2024-03-31 | 4.61M | -78.8% |
| FY2022 | 2023-03-31 | 21.72M | -32.7% |
| FY2021 | 2022-03-31 | 32.26M | — |
Research & Development vs competitors
How CGC compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -100.0% is the lowest of 9, against a peer median of +13.7%.
- Research & development amounts to 0.0% of revenue for CGC, versus a peer median of 18.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $151.83M USD | -11.7% | -0.1% | 489780.6% | |
| LTM Mar 2026 | $151.01M USD | +44.8% | +53.7% | — | |
| LTM Mar 2026 | $88.26M USD | -21.9% | +29.1% | 24.4% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $83.27M USD | +36.9% | +34.3% | 807.2% |
| LTM Mar 2026 | $56.72M USD | +60.6% | -12.2% | 677.9% | |
| LTM Mar 2026 | $31.97M USD | -10.4% | -0.1% | 13.4% | |
| LTM Mar 2026 | $7.58M USD | — | +1.8% | 5.6% | |
| LTM Mar 2026 | CA$4.98M CAD | +35.4% | +1.4% | 1.6% | |
| LTM Mar 2026 | $2.25M USD | -8.0% | -34.3% | 5.4% | |
| LTM Mar 2026 | CA$0 CAD | -100.0% | — | 0.0% | |
| Peer median (excluding CGC) | — | +13.7% | +1.4% | 18.9% | |
Competitors are the stored peer set for CGC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Mar 2022 | FY2022 Mar 2023 | FY2023 Mar 2024 | FY2024 Mar 2025 | FY2025 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 475.7M | 333.25M | 297.15M | 269M | 483.67M |
| Cost of Revenue | 663.11M | 396.78M | 216.26M | 189.48M | 386.51M |
| Gross Profit | (187.41M) | (63.53M) | 80.88M | 79.51M | 97.16M |
| Gross Margin | -39.4% | -19.1% | 27.2% | 29.6% | 20.1% |
| Research & Development | 32.26M | 21.72M | 4.61M | 1.91M | 0 |
| Selling, General & Admin | 361.1M | 297.98M | 180.59M | 121.71M | 223.11M |
| Operating Expenses | 831.39M | 2.57B | 309.6M | 196.65M | 322.6M |
| Depreciation & Amortization | 110.94M | 80.03M | 53.18M | 43.12M | 50.86M |
| EBITDA | (52.98M) | (2.88B) | (312.83M) | (479.31M) | 50.86M |
| EBITDA Margin | -11.1% | -864.2% | -105.3% | -178.2% | 10.5% |
| Operating Income | (1.02B) | (2.63B) | (228.71M) | (117.14M) | (161.66M) |
| Operating Margin | -214.2% | -789.3% | -77.0% | -43.5% | -33.4% |
| Interest Income | 6.6M | 24.28M | 16.24M | 8.82M | 10M |
| Interest Expense | 103.94M | 126.16M | 105.35M | 74.57M | 38.19M |
| Other Income / Expenses | 750.94M | (455.64M) | (242.64M) | (479.85M) | (101.23M) |
| Income Before Tax | (267.86M) | (3.09B) | (471.36M) | (597M) | (262.89M) |
| Pre-Tax Margin | -56.3% | -926.1% | -158.6% | -221.9% | -54.4% |
| Income Tax Expense | (8.95M) | (5.73M) | 12.33M | 7.14M | 23K |
| Net Income | (310.04M) | (3.28B) | (657.27M) | (598.12M) | (366.64M) |
| Net Margin | -65.2% | -983.7% | -221.2% | -222.4% | -75.8% |
| EPS (Basic) | (7.70) | (70.70) | (6.47) | (5.53) | (0.88) |
| EPS (Diluted) | (7.70) | (70.70) | (8.79) | (5.53) | (0.88) |
| Weighted Avg Shares | 39.13M | 46.37M | 101.63M | 107.55M | 2.98B |
| Weighted Avg Shares (Diluted) | 39.13M | 46.37M | 74.79M | 107.55M | 2.98B |
Canopy Growth Corporation
NASDAQ:CGC
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.